Clinical Medical College, Chengdu Medical College, Chengdu 610500, Sichuan Province, China.
Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Sichuan Province, China.
World J Gastroenterol. 2023 Sep 28;29(36):5240-5253. doi: 10.3748/wjg.v29.i36.5240.
The diagnostic value of combined methylated branched chain amino acid transaminase 1 (BCAT1)/IKAROS family zinc finger 1 (IKZF1) in plasma for colorectal cancer (CRC) has been explored since 2015. Recently, several related studies have published their results and showed its diagnostic efficacy.
To analyze the diagnostic value of methylated BCAT1/IKZF1 in plasma for screening and postoperative follow-up of CRC.
The candidate studies were identified by searching the PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases from May 31, 2003 to June 1, 2023. Sensitivity, specificity, and diagnostic accuracy were calculated by merging ratios or means.
Twelve eligible studies were included in the analysis, involving 6561 participants. The sensitivity of methylated BCAT1/IKZF1 in plasma for CRC diagnosis was 60% [95% confidence interval (CI) 53-67] and specificity was 92% (95%CI: 90-94). The positive and negative likelihood ratios were 8.0 (95%CI: 5.8-11.0) and 0.43 (95%CI: 0.36-0.52), respectively. Diagnostic odds ratio was 19 (95%CI: 11-30) and area under the curve was 0.88 (95%CI: 0.85-0.91). The sensitivity and specificity for CRC screening were 64% (95%CI: 59-69) and 92% (95%CI: 91-93), respectively. The sensitivity and specificity for recurrence detection during follow-up were 54% (95%CI: 42-67) and 93% (95%CI: 88-96), respectively.
The detection of methylated BCAT1/IKZF1 in plasma, as a non-invasive detection method of circulating tumor DNA, has potential CRC diagnosis, but the clinical application prospect needs to be further explored.
自 2015 年以来，已探索了联合使用血液中甲基化支链氨基酸转氨酶 1（BCAT1）/IKAROS 家族锌指蛋白 1（IKZF1）进行结直肠癌（CRC）诊断的价值。最近，有几项相关研究发表了他们的结果，并显示了其诊断功效。
分析血液中甲基化 BCAT1/IKZF1 对 CRC 筛查和术后随访的诊断价值。
通过检索 PubMed、Embase、Cochrane 图书馆、中国知网和万方数据库，从 2003 年 5 月 31 日至 2023 年 6 月 1 日，确定候选研究。通过合并比值或平均值计算敏感性、特异性和诊断准确性。
纳入的 12 项研究进行了分析，涉及 6561 名参与者。血液中甲基化 BCAT1/IKZF1 对 CRC 诊断的敏感性为 60%（95%置信区间：53-67），特异性为 92%（95%置信区间：90-94）。阳性和阴性似然比分别为 8.0（95%置信区间：5.8-11.0）和 0.43（95%置信区间：0.36-0.52）。诊断优势比为 19（95%置信区间：11-30），曲线下面积为 0.88（95%置信区间：0.85-0.91）。CRC 筛查的敏感性和特异性分别为 64%（95%置信区间：59-69）和 92%（95%置信区间：91-93）。随访期间检测复发的敏感性和特异性分别为 54%（95%置信区间：42-67）和 93%（95%置信区间：88-96）。
作为一种循环肿瘤 DNA 的非侵入性检测方法，血液中甲基化 BCAT1/IKZF1 的检测具有潜在的 CRC 诊断价值，但需要进一步探索其临床应用前景。
